Scarica l'app Stockscreener
26.71
0.19%
0.05
Dopo l'orario di chiusura:
26.69
-0.02
-0.07%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Kalvista Pharmaceuticals Inc Borsa (KALV) Ultime notizie
Chiesi Farmaceutici (NASDAQ: KALV) offers $27.00 per share to buy KalVista - Stock Titan
KalVista climbs as Italy’s Chiesi agrees to acquire in $1.9B deal - MSN
Are XOMA, RMAX, KALV Obtaining Fair Deals for their Shareholders? - Sahm
Chiesi to buy KalVista Pharmaceuticals for $1.9 billion - MSN
Avoiding Lag: Real-Time Signals in (KALV) Movement - Stock Traders Daily
HC Wainwright & Co. downgrades KalVista Pharmaceuticals (KALV) - MSN
KalVista Pharmaceuticals | SCHEDULE 13G/A: Others - Moomoo
Millennium group reports shared control of 1.9M KalVista shares (KALV) - Stock Titan
KALV Downgraded by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
KalVista Pharmaceuticals 2025 Executive Compensation, Equity Awards, and Corporate Governance Highlights - Minichart
KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc.KALV - Business Wire
H.C. Wainwright Downgrades KalVista Pharmaceuticals(KALV.US) to Hold Rating, Cuts Target Price to $27 - Moomoo
KalVista Pharmaceuticals (NASDAQ:KALV) Rating Lowered to "Neutral" at HC Wainwright - MarketBeat
Kalvista Pharmaceuticals stock rating cut to neutral by H.C. Wainwright on merger deal - Investing.com Nigeria
KalVista Pharmaceuticals (NASDAQ:KALV) Stock Rating Lowered by JonesTrading - MarketBeat
KalVista Pharmaceuticals (NASDAQ:KALV) Downgraded by Leerink Partners to Hold - MarketBeat
KalVista Pharmaceuticals (NASDAQ:KALV) Downgraded by Citizens Jmp to Hold - MarketBeat
Needham Downgrades KalVista Pharmaceuticals(KALV.US) to Hold Rating - Moomoo
KalVista Pharmaceuticals | 10-KT/A: Others - Moomoo
IBT portfolio manager says KalVista deal signals Biotech 2.0 growth - Proactive financial news
Chiesi widens rare disease portfolio with $1.9bn KalVista buyout - MSN
KalVista (NASDAQ: KALV) amends 10-KT, reveals April 29, 2026 merger deal with Chiesi - Stock Titan
KALV Downgraded by Needham -- Rating Changed to Hold - GuruFocus
KalVista Pharmaceuticals (NASDAQ:KALV) Given "Hold" Rating at Needham & Company LLC - MarketBeat
Hereditary Angioedema Market: Rapid Increment Driven by Innovation by 2034DelveInsight - openPR.com
KalVista Pharmaceuticals (NASDAQ:KALV) Sees Large Volume IncreaseHere's Why - MarketBeat
Chiesi commits $1.9bn to rare disease expansion with KalVista Buy - BioXconomy
Jones Trading downgrades Kalvista stock to hold on Chiesi acquisition By Investing.com - Investing.com South Africa
Jones Trading downgrades Kalvista stock to hold on Chiesi acquisition - Investing.com
Italy: Chiesi Group expanding global Rare Disease portfolio with US$1.9bn acquisition of KalVista - Investors in Healthcare
Shorted-to-The-Hilt KalVista Rockets 39% as Chiesi Swoops in With $1.9bn Cash Bid - NAI500
Leerink Partners Downgrades KalVista Pharmaceuticals(KALV.US) to Hold Rating, Announces Target Price $27 - Moomoo
KalVista Downgraded to $27 Target as Chiesi’s All-Cash Takeout Caps Near-Term Upside, Supporting Hold Rating - TipRanks
Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio - 투데이안
JonesTrading Downgrades KalVista Pharmaceuticals(KALV.US) to Hold Rating, Cuts Target Price to $27 - Moomoo
DRI Healthcare Trust Evaluates Royalty Agreement With KalVista After Chiesi Deal Proposal - Moomoo
Stock Market Today, April 29: KalVista Pharmaceuticals Surges on Chiesi Group Acquisition Announcement - The Motley Fool
KalVista Pharmaceuticals | SC14D9C: Written communication by the subject company relating to a third party tender offermoomoo - Moomoo
Chiesi Grows Again In Rare Diseases With Its Largest Deal Yet, Buying KalVista - Citeline News & Insights
Sector Update: Health Care Stocks Fall Late Afternoon - Moomoo
Chiesi to acquire KalVista Pharmaceuticals for $1.9 billion By Investing.com - Investing.com Australia
DRI Healthcare Trust Comments on Proposed Acquisition of KalVista Therapeutics, Inc. - Newswire Canada
Biotech Scores $1.9 Billion Deal; Why A Key Rival Also Jumped - Investor's Business Daily
Deal And Earnings Wins Powered A Big Day For Three Stocks - Finimize
Italian drugmaker Chiesi to buy KalVista for $1.9 billion - Classic Rock 103.5 WIMZ
CPI | Italian Drugmaker to Buy KalVista for $1.9 Billion - PYMNTS.com
Chiesi Group Grows Again in Rare Disease With $1.9B KalVista Acquisition - MedCity News
KalVista (KALV) Receives No Rating Following Acquisition Announcement - GuruFocus
Regeneron Pharmaceuticals Inc Stock (REGN) Moved Down by 7.82% on Apr 29: Facts Behind the Movement - TradingKey
KALV Stock Alert: Halper Sadeh LLC is Investigating Whether KalVista Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders - Business Wire
KalVista moved to No Rating at BofA - TipRanks
KalVista: 'Strong Buy' As Acquired By Chiesi And Positive KONFIDENT-KID Outcome (KALV) - Seeking Alpha
KALV Stock Alert: Halper Sadeh LLC is Investigating Whether KalVi - The National Law Review
KalVista Pharmaceuticals (NASDAQ:KALV) Hits New 12-Month HighShould You Buy? - MarketBeat
Ademi LLP Investigates Whether KalVista Pharmaceuticals Inc. Is Obtaining a Fair Price for Public Shareholders - 富途牛牛
Chiesi snags on-demand HAE drug in $1.9B Kalvista buy - BioWorld News
Italian Pharma Group Chiesi to Acquire U.S. Rival KalVista - marketscreener.com
Italian biopharma Chiesi acquires Massachusetts biotech in $1.9B deal - The Business Journals
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):